Mitsubishi UFJ Asset Management Co. Ltd and other financial companies and firms such as
Virtu Financial,
Public Sector Pension Investment Board,
Headlands Technologies, and
Allianz Asset Management, have recently increased their stock holdings in
Teva Pharmaceutical Industries Ltd. Asset managers and analysts like
David Einhorn and
Larry Robbins are suggesting Teva as a profitable investment. Notably, the stock has been upgraded and reiterated at 'Buy' by institutions like
BofA,
Leader Capital Markets, and
Goldman Sachs, alongside seeing an
RS Rating Upgrade. However, the stock has experienced fluctuations recently, with shareholders experiencing both success and losses. It saw a 14% dip in stock price, later recovering with a 14% rise following FDA acceptance of a new drug application. Insiders sales reports show considerable amounts sold by executives, which might imply insider pessimism. Teva's CEO announced ongoing progress with their 'Pivot to Growth' strategy, indicating a focus on expansion and development. Despite regional risks, analysts are suggesting to keep an eye on the stock.
Teva Pharmaceutical Stocks News Analytics from Wed, 06 Nov 2024 08:00:00 GMT to Sat, 16 Aug 2025 21:33:32 GMT -
Rating 7
- Innovation 4
- Information 8
- Rumor -3
